Hodgkin's disease - The authors reply Journal Article

  


Authors: DeVita, V. T. Jr; Hubbard, S. M.
Article Title: Hodgkin's disease - The authors reply
Abstract: To the Editor: In their review of drug therapy for Hodgkin's disease (Feb. 25 issue),1 DeVita and Hubbard cite two trials conducted to compare chemotherapy alone with radiotherapy alone as treatment for stage I or II Hodgkin's disease2,3. They stated that both trials demonstrated that “combination therapy was as effective as radiotherapy.” The overall survival in the study by Biti et al.,2 with a median follow-up of eight years, however, was significantly higher among patients treated with radiotherapy than among those treated with chemotherapy (93 percent vs. 56 percent, P<0.001). Furthermore, the survival among patients who relapsed after... © 1993, Massachusetts Medical Society. All rights reserved.
Keywords: cancer survival; prednisone; cancer combination chemotherapy; multimodality cancer therapy; cancer radiotherapy; combined modality therapy; cancer staging; follow up; letter; relapse; vincristine; chlormethine; procarbazine; hodgkin disease; human; priority journal
Journal Title: New England Journal of Medicine
Volume: 329
Issue: 5
ISSN: 0028-4793
Publisher: Massachusetts Medical Society  
Date Published: 1993-07-29
Start Page: 361
End Page: 362
Language: English
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027250371&doi=10.1056%2fNEJM199307293290515&partnerID=40&md5=6f2c71ee947aa8da5db054d2212d5016
Notes: For full correspondence, see PMID: 8321272, DOI: 10.1056/nejm199307293290515 -- For original publication, see PMID: 8426624, DOI: 10.1056/NEJM199302253280808 Source: Scopus
MSK Authors
  1. Vincent T. DeVita Jr
    17 DeVita
Related MSK Work